Fingolimod (FTY720) Inhibits BCR-ABL Signaling Allosterically by Binding to the Myristate Binding Site

被引：0
|
作者：
Manley, Paul W. [1 ]
Cowan-Jacob, Sandra W. [1 ]
Cozens, Robert [1 ]
Fendrich, Gabriele [1 ]
Jahnke, Wolfgang [1 ]
Roesel, Johannes L. [1 ]
Fabbro, Dorian [1 ]
机构：
[1] Novartis Inst Biomed Res, Basel, Switzerland
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1181 / 1181
页数：1
相关论文
共 50 条
  • [41] S1P1 receptor signaling on cells of astrocytic lineages in experimental autoimmune encephalomyelitis: a role in disease progression and the efficacy of fingolimod (FTY720)
    Choi, Ji W.
    Herr, Deron
    Lee, Chang-Wook
    Teo, Siew
    Kennedy, Grace
    Chun, Jerold
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 : S37 - S37
  • [42] Fingolimod (FTY720) Activates Protein Phosphatase-2A in Human Monocytes and Inhibits Uric Acid Crystal-Induced Interleukin-1 Beta Production
    Elsayed, Sandy
    Qadri, Marwa
    Elsaid, Khaled
    FASEB JOURNAL, 2020, 34
  • [43] (S)-M720-Vinylphosphonate, an analogue of the immunosuppressive agent FTY720, is a pan-antagonist of sphingosine 1-phosphate GPCR signaling and inhibits autotaxin activity
    Valentine, William J.
    Kiss, Gyoengyi N.
    Liu, Jianxiong
    Shuyu, E.
    Gotoh, Mari
    Murakami-Murofushi, Kimiko
    Pham, Truc Chi
    Baker, Daniel L.
    Parrill, Abby L.
    Lu, Xuequan
    Sun, Chaode
    Bittman, Robert
    Pyne, Nigel J.
    Tigyi, Gabor
    CELLULAR SIGNALLING, 2010, 22 (10) : 1543 - 1553
  • [44] Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity
    Pippa, R.
    Dominguez, A.
    Christensen, D. J.
    Moreno-Miralles, I.
    Blanco-Prieto, M. J.
    Vitek, M. P.
    Odero, M. D.
    LEUKEMIA, 2014, 28 (09) : 1915 - 1918
  • [45] The interaction of the Bcr-Abl tyrosine kinase with the Src-kinase Hck is mediated by at least three binding regions in Bcr-Abl and by the Sh3/Sh2 domains of Hck.
    Stanglmaier, M
    Kleinlein, I
    Warmuth, M
    Häuslmann, K
    Hallek, M
    BLOOD, 1998, 92 (10) : 221A - 221A
  • [46] Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity
    R Pippa
    A Dominguez
    D J Christensen
    I Moreno-Miralles
    M J Blanco-Prieto
    M P Vitek
    M D Odero
    Leukemia, 2014, 28 : 1915 - 1918
  • [47] The ABL actin-binding domain is not essential for induction of myeloproliferative disorder by BCR-ABL in mice but it affects the phenotype of a myeloid disease induced by TEL-ABL.
    Perera, SA
    Ren, RB
    BLOOD, 2001, 98 (11) : 468A - 468A
  • [48] EFFECT OF FTY720 ON THE SET-PP2A COMPLEX IN ACUTE MYELOID LEUKEMIA. SET BINDING DRUGS HAVE ANTAGONISTIC ACTIVITY
    Pippa, R.
    Dominguez, A.
    Christensen, D. J.
    Moreno-Miralles, I.
    Blanco-Prieto, M.
    Bachs, O.
    Ye, K.
    Vitek, M. P.
    Odero, M. D.
    HAEMATOLOGICA, 2014, 99 : 796 - 796
  • [49] WP1130 Inhibits Signaling through BCR-ABL Ubiquitination and Cytoplasmic to Aggresome Trafficking to Induce Apoptosis of CML Cells
    Donato, Nicholas J.
    Sun, Hanshi
    Kapuria, Vaibhav
    Peterson, Luke F.
    Bartholomeusz, Geoffrey
    Bornmann, William G.
    Talpaz, Moshe
    BLOOD, 2009, 114 (22) : 1281 - 1281
  • [50] ND-09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR-ABL signaling
    Liu, Yan-Hong
    Zhu, Man
    Lei, Pan-Pan
    Pan, Xiao-Yan
    Ma, Wei-Na
    ONCOLOGY REPORTS, 2021, 46 (01)
12345